119 related articles for article (PubMed ID: 11158250)
1. Clozapine increases apolipoprotein D expression in rodent brain: towards a mechanism for neuroleptic pharmacotherapy.
Thomas EA; Danielson PE; Nelson PA; Pribyl TM; Hilbush BS; Hasel KW; Sutcliffe JG
J Neurochem; 2001 Feb; 76(3):789-96. PubMed ID: 11158250
[TBL] [Abstract][Full Text] [Related]
2. Antipsychotic drug treatment alters expression of mRNAs encoding lipid metabolism-related proteins.
Thomas EA; George RC; Danielson PE; Nelson PA; Warren AJ; Lo D; Sutcliffe JG
Mol Psychiatry; 2003 Nov; 8(12):983-93, 950. PubMed ID: 14647396
[TBL] [Abstract][Full Text] [Related]
3. Clozapine specifically alters the arachidonic acid pathway in mice lacking apolipoprotein D.
Thomas EA; Yao JK
Schizophr Res; 2007 Jan; 89(1-3):147-53. PubMed ID: 17011169
[TBL] [Abstract][Full Text] [Related]
4. Antipsychotic drugs differentially modulate apolipoprotein D in rat brain.
Khan MM; Parikh VV; Mahadik SP
J Neurochem; 2003 Sep; 86(5):1089-100. PubMed ID: 12911617
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic characterization of neuroleptic-sensitive neurons in the forebrain: contrasting targets of haloperidol and clozapine.
Guo N; Vincent SR; Fibiger HC
Neuropsychopharmacology; 1998 Aug; 19(2):133-45. PubMed ID: 9629567
[TBL] [Abstract][Full Text] [Related]
6. Cellular cholesterol storage in the Niemann-Pick disease type C mouse is associated with increased expression and defective processing of apolipoprotein D.
Suresh S; Yan Z; Patel RC; Patel YC; Patel SC
J Neurochem; 1998 Jan; 70(1):242-51. PubMed ID: 9422368
[TBL] [Abstract][Full Text] [Related]
7. Molecular characterization and developmental expression pattern of the chicken apolipoprotein D gene: implications for the evolution of vertebrate lipocalins.
Ganfornina MD; Sánchez D; Pagano A; Tonachini L; Descalzi-Cancedda F; Martínez S
Dev Dyn; 2005 Jan; 232(1):191-9. PubMed ID: 15580625
[TBL] [Abstract][Full Text] [Related]
8. From pharmacotherapy to pathophysiology: emerging mechanisms of apolipoprotein D in psychiatric disorders.
Thomas EA; Copolov DL; Sutcliffe JG
Curr Mol Med; 2003 Aug; 3(5):408-18. PubMed ID: 12942994
[TBL] [Abstract][Full Text] [Related]
9. Clozapine administered repeatedly following pretreatment with ketamine enhances dopamine D
Szlachta M; Kuśmider M; Solich J; Kolasa M; Pabian P; Dziedzicka-Wasylewska M; Faron-Górecka A
Neurosci Lett; 2019 Aug; 707():134292. PubMed ID: 31132389
[TBL] [Abstract][Full Text] [Related]
10. Molecular characterization and differential mRNA tissue distribution of mouse apolipoprotein D.
Séguin D; Desforges M; Rassart E
Brain Res Mol Brain Res; 1995 Jun; 30(2):242-50. PubMed ID: 7637575
[TBL] [Abstract][Full Text] [Related]
11. Increased CNS levels of apolipoprotein D in schizophrenic and bipolar subjects: implications for the pathophysiology of psychiatric disorders.
Thomas EA; Dean B; Pavey G; Sutcliffe JG
Proc Natl Acad Sci U S A; 2001 Mar; 98(7):4066-71. PubMed ID: 11274430
[TBL] [Abstract][Full Text] [Related]
12. Modulation of apolipoprotein D and apolipoprotein E mRNA expression by growth arrest and identification of key elements in the promoter.
Do Carmo S; Séguin D; Milne R; Rassart E
J Biol Chem; 2002 Feb; 277(7):5514-23. PubMed ID: 11711530
[TBL] [Abstract][Full Text] [Related]
13. Apolipoprotein D mediates autocrine protection of astrocytes and controls their reactivity level, contributing to the functional maintenance of paraquat-challenged dopaminergic systems.
Bajo-Grañeras R; Ganfornina MD; Martín-Tejedor E; Sanchez D
Glia; 2011 Oct; 59(10):1551-66. PubMed ID: 21688324
[TBL] [Abstract][Full Text] [Related]
14. Control of the neuroprotective Lipocalin Apolipoprotein D expression by alternative promoter regions and differentially expressed mRNA 5' UTR variants.
Diez-Hermano S; Mejias A; Sanchez D; Gutierrez G; Ganfornina MD
PLoS One; 2020; 15(6):e0234857. PubMed ID: 32559215
[TBL] [Abstract][Full Text] [Related]
15. Chronic treatments with haloperidol and clozapine alter the level of NMDA-R1 mRNA in the rat brain: an in situ hybridization study.
Ossowska K; Pietraszek M; Wardas J; Dziedzicka-Wasylewska M; Nowicka D; Wolfarth S
Pol J Pharmacol; 2002; 54(1):1-9. PubMed ID: 12020038
[TBL] [Abstract][Full Text] [Related]
16. Cellular localization of apolipoprotein D and lecithin:cholesterol acyltransferase mRNA in rhesus monkey tissues by in situ hybridization.
Smith KM; Lawn RM; Wilcox JN
J Lipid Res; 1990 Jun; 31(6):995-1004. PubMed ID: 2373967
[TBL] [Abstract][Full Text] [Related]
17. A gene expression and systems pathway analysis of the effects of clozapine compared to haloperidol in the mouse brain implicates susceptibility genes for schizophrenia.
Rizig MA; McQuillin A; Ng A; Robinson M; Harrison A; Zvelebil M; Hunt SP; Gurling HM
J Psychopharmacol; 2012 Sep; 26(9):1218-30. PubMed ID: 22767372
[TBL] [Abstract][Full Text] [Related]
18. Neuropeptide Y mRNA expression levels following chronic olanzapine, clozapine and haloperidol administration in rats.
Huang XF; Deng C; Zavitsanou K
Neuropeptides; 2006 Jun; 40(3):213-9. PubMed ID: 16516965
[TBL] [Abstract][Full Text] [Related]
19. Apolipoprotein D mRNA expression is elevated in PDAPP transgenic mice.
Thomas EA; Sautkulis LN; Criado JR; Games D; Sutcliffe JG
J Neurochem; 2001 Dec; 79(5):1059-64. PubMed ID: 11739619
[TBL] [Abstract][Full Text] [Related]
20. Apolipoprotein D in the Niemann-Pick type C disease mouse brain: an ultrastructural immunocytochemical analysis.
Ong WY; Hu CY; Patel SC
J Neurocytol; 2002 Feb; 31(2):121-9. PubMed ID: 12815234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
